The estimated Net Worth of Spyros Papapetropoulos is at least $85.2 Tisíc dollars as of 22 November 2022. Spyros Papapetropoulos owns over 21,739 units of Lipocine Inc stock worth over $85,217 and over the last 4 years Spyros sold LPCN stock worth over $0.
Sign up
Spyros Papapetropoulos LPCN stock SEC Form 4 insiders trading
Spyros has made over 2 trades of the Lipocine Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Spyros bought 21,739 units of LPCN stock worth $10,217 on 22 November 2022.
The largest trade Spyros's ever made was buying 21,739 units of Lipocine Inc stock on 22 November 2022 worth over $10,217. On average, Spyros trades about 3,079 units every 69 days since 2020. As of 22 November 2022 Spyros still owns at least 21,739 units of Lipocine Inc stock.
You can see the complete history of Spyros Papapetropoulos stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Spyros Papapetropoulos's mailing address?
Spyros's mailing address filed with the SEC is 675 ARAPEEN DRIVE SUITE 202, , SALT LAKE CITY, UT, 84108.
Insiders trading at Lipocine Inc
Over the last 11 years, insiders at Lipocine Inc have traded over $9,045 worth of Lipocine Inc stock and bought 890,945 units worth $696,169 . The most active insiders traders include Mahesh V. Patel, John W. Higuchi a Morgan R Brown. On average, Lipocine Inc executives and independent directors trade stock every 72 days with the average trade being worth of $148,846. The most recent stock trade was executed by Mahesh V. Patel on 25 May 2023, trading 8,706 units of LPCN stock currently worth $43,791.
What does Lipocine Inc do?
lipocine inc., a specialty pharmaceutical company, develops and commercializes pharmaceutical products. the company develops drugs based on hydroance, a drug delivery technology. it primarily focuses on developing oral versions of several hormones for use in men and women health. the company’s lipid-based technology platform offers non-invasive delivery solutions for small polar organics and macromolecules. it also offers custom drugs for pharmaceutical/biotechnology companies. lipocine inc. was founded in 1997 and is headquartered in salt lake city, utah.
What does Lipocine Inc's logo look like?
Complete history of Spyros Papapetropoulos stock trades at Adamas Pharmaceuticals Inc a Lipocine Inc
Lipocine Inc executives and stock owners
Lipocine Inc executives and other stock owners filed with the SEC include:
-
Mahesh Patel,
Chairman of the Board, President, Chief Executive Officer -
Dr. Mahesh V. Patel Ph.D.,
Co-Founder, Interim Principal Financial Officer, Chairman, Pres & CEO -
Dr. Mahesh V. Patel,
Co-Founder, Chairman, Pres & CEO -
Morgan R. Brown CPA, CPA, M.B.A., MBA,
Corp. Sec. -
Morgan R. Brown CPA, M.B.A., CPA, MBA,
Exec. VP, CFO, Principal Accounting Officer & Corp. Sec. -
Morgan Brown,
Chief Financial Officer, Executive Vice President -
Nachiappan Chidambaram Ph.D.,
VP of Product Devel. -
John Higuchi,
Non-Executive Director -
Richard Ono,
Director -
Jeffrey Fink,
Director -
Stephen Hill,
Lead Independent Director -
Krista Fogarty,
Principal Accounting Officer & Corp. Controller -
Dr. Anthony DelConte M.D., M. D.,
Chief Medical Director -
Logan Morse,
VP of Sales, Marketing & Operations -
Jyrki Mattila,
Chief Business Officer -
Gregory Brooks Bass,
EVP and Chief Commercial Offic -
Srinivasan Venkateshwaran,
CTO and VP RandD -
Gerald T Simmons,
VP Corp Business Development -
Robert K. Merrell,
VP Finance -
Jill M. Jene,
Director -
Spyros Papapetropoulos,
Director -
Krista Fogarty,
Principal Accounting Officer -
George Nomikos,
Chief Medical Officer